Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | HTR2B | P41595 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496848 | 0.73 | HTR2A (0.55) | HTR2CHTR2BHTR2ACRBN | |
| SCHEMBL2499345 | 0.72 | HTR2C (0.47) | HTR2CHTR2BHTR2ACRBNSIGMAR1 | |
| Hydrochloric Acid SCHEMBL2492938 | 0.72 | HTR2A (0.54) | HTR2CHTR2BHTR2ACRBN | |
| Hydrochloric Acid SCHEMBL2493252 | 0.71 | HTR2C (0.46) | HTR2CHTR2BHTR2ACRBNSIGMAR1 | |
| SCHEMBL13673173 | 0.70 | HTR2A (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL1105041 | 0.70 | HTR2C (0.60) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL24175762 | 0.69 | HTR2A (0.35) | HTR2CHTR2BHTR2AGAANPC1 | |
| SCHEMBL21762549 | 0.69 | HTR2C (0.64) | HTR2CHTR2BHTR2AGAADRD1 | |
| SCHEMBL10324926 | 0.68 | HTR2A (0.41) | HTR2CHTR2BHTR2AGAANPC1 | |
| SCHEMBL2496854 | 0.68 | SIGMAR1 (0.52) | HTR2CHTR2BHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010523-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | NR3C2, DRD3, TACR1 | HTR2C 170/4885HTR2B 517/4885HTR2A 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.